Methods of treating frontal temporal dementia (ftd) with comprising administering metal chelators to the upper one-third of the nasal cavity

Abstract

The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is disclosed which comprises DFO and in certain embodiments combines DFO with one or more of the psychotropic drug types, i.e., antipsychotics, mood stabilizers and antidepressants. Moreover, a treatment for treating impairment of neural plasticity through inhibition of GSK3b is provided as well as prevention of apoptosis of cells through inhibition of GSK3b.

1 - 20 . (canceled) 
     
     
         21 . A method to treat a patient with frontal temporal dementia comprising:
 administering at least one effective dose of deferoxamine (DFO) to the upper one-third of the patient's nasal cavity, wherein the at least one effective dose of DFO is 0.0001 to 1.0 mg/kg;   thereby enabling the at least one effective dose of DFO to bypass the patient's blood-brain barrier and delivering the at least one effective dose of DFO to the patient's central nervous system; and   treating the frontal temporal dementia.   
     
     
         22 . The method of  claim 21 , wherein the administration of the at least one effective dose of DFO treats neurodegeneration in the patient, wherein the neurodegeneration is caused by frontal temporal dementia. 
     
     
         23 . The method of  claim 21 , wherein the administration of DFO inhibits memory loss caused by frontal temporal dementia. 
     
     
         24 . The method of  claim 21 , wherein the administration of the at least one effective dose of DFO treats physical impairment of the patient, wherein the physical impairment is caused by frontal temporal dementia. 
     
     
         25 . The method of  claim 21 , wherein the administration of the at least one effective dose of DFO treats behavioral impairment of the patient, wherein the behavioral impairment is caused by frontal temporal dementia. 
     
     
         26 . The method of  claim 21 , further comprising the at least one effective dose of DFO having a volume of 0.015 to 1.0 ml. 
     
     
         27 . The method of  claim 21 , wherein the at least one effective dose of DFO is 0.005 to 1.0 mg/kg. 
     
     
         28 . The method of  claim 21 , further comprising administering the at least one dose of DFO until the concentration of DFO in the patient's brain is within the range of 0.1 nM to 50 μM. 
     
     
         29 . The method of  claim 21 , wherein the at least one effective dose of DFO is administered to the upper one-third of the patient's nasal cavity as a liquid spray. 
     
     
         30 . The method of  claim 21 , wherein the at least one effective dose of DFO is administered to the upper one-third of the patient's nasal cavity as a powdered spray. 
     
     
         31 . The method of  claim 21 , wherein the at least one effective dose of DFO is administered to the upper one-third of the patient's nasal cavity as nose drops. 
     
     
         32 . The method of  claim 21 , wherein the at least one effective dose of DFO is administered to the upper one-third of the patient's nasal cavity as a gel. 
     
     
         33 . The method of  claim 21 , wherein the at least one effective dose of DFO is administered to the upper one-third of the patient's nasal cavity as an ointment. 
     
     
         34 . A method to treat a patient with frontal temporal dementia comprising:
 administering at least one effective dose of a metal chelator to the upper one-third of the patient's nasal cavity, wherein the at least one effective dose of the metal chelator is 0.0001 to 1.0 mg/kg;   thereby enabling the at least one effective dose of the metal chelator to bypass the patient's blood-brain barrier and delivering the at least one effective dose of the metal chelator to the patient's central nervous system; and   treating the frontal temporal dementia.   
     
     
         35 . The method of  claim 34 , wherein the metal chelator comprises an iron chelator or a copper chelator. 
     
     
         36 . The method of  claim 34 , wherein the administration of the at least one effective dose of the metal chelator treats neurodegeneration in the patient, wherein the neurodegeneration is caused by frontal temporal dementia. 
     
     
         37 . The method of  claim 34 , wherein the administration of the at least one effective dose of the metal chelator inhibits memory loss caused by frontal temporal dementia. 
     
     
         38 . The method of  claim 34 , wherein the administration of the at least one effective dose of the metal chelator treats physical impairment of the patient, wherein the physical impairment is caused by frontal temporal dementia. 
     
     
         39 . The method of  claim 34 , wherein the administration of the at least one effective dose of the metal chelator treats behavioral impairment of the patient, wherein the behavioral impairment is caused by frontal temporal dementia. 
     
     
         40 . The method of  claim 34 , further comprising the at least one effective dose of the metal chelator having a volume of 0.015 to 1.0 ml. 
     
     
         41 . The method of  claim 34 , wherein the at least one effective dose of the metal chelator is 0.005 to 1.0 mg/kg. 
     
     
         42 . The method of  claim 34 , further comprising administering the at least one dose of the metal chelator until the concentration of the metal chelator in the patient's brain is within the range of 0.1 nM to 50 μM. 
     
     
         43 . The method of  claim 34 , wherein the at least one effective dose of the metal chelator is administered to the upper one-third of the patient's nasal cavity as one of the group consisting of: a liquid spray, a powdered spray, nose drops, a gel, and an ointment.